GlaxoSmithKline's talk of leaving rare diseases—amid slow Strimvelis sales—highlights challenges

Fierce Pharma ------- GlaxoSmithKline’s decision to explore a sale for its rare disease unit offers an opportunity for those who may be eyeing the field, but it's also another warning sign that drugmakers can struggle to find a market for their expensive gene therapies. And with Novartis and Kite Pharma on the verge of approvals for cancer treatments of that ilk—likely to be quite pricey—more companies will face similar challenges. After conducting a review of its rare diseases unit, GSK on Wednesday disclosed it is “considering options for future ownership of these assets.” The group includes Strimvelis, a $665,000 treatment for the rare immune system disorder ADA-SCID, and two other programs in development. To learn more click on the picture below to read the article.